| Autor: |
Romero-Sánchez, M. Concepción, Machmach, Kawthar, Gonzalez-Serna, Alejandro, Genebat, Miguel, Pulido, Ildefonso, García-García, María, Álvarez-Ríos, Ana Isabel, Ferrando-Martinez, Sara, Ruiz-Mateos, Ezequiel, Leal, Manuel |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; August 2012, Vol. 56 Issue: 11 p5858-5864, 7p |
| Abstrakt: |
ABSTRACTThe potential effect of blocking the CCR5 receptor on HIV disease progression biomarkers is not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test (MCT) can be used in selecting patients to receive MVC-containing combined antiretroviral therapy (cART). Using this MCT model, we assessed the effect of MVC on several HIV disease progression biomarkers during the MCT (MVC-specific effect) and following short-term (12-week) cART. We compared 45 patients on MVC monotherapy with a control group of 25 patients on MVC-sparing cART. We found that MVC did not modify any biomarkers in patients that had no virological response after the MCT. MVC-specific effects in patients with virological responses included increased CD8+T-cell activation and senescence levels, preservation of an increase in soluble CD14 (sCD14), and a decrease in D dimer levels. After 12 weeks, MVC-containing cART increased CD8+T-cell counts and preserved CD4+T-cell senescence levels compared with MVC-sparing cART. Moreover, there was a decrease in sCD14 levels in patients that received MVC-containing cART. In conclusion, effects compatible with CD8+T-cell redistribution in peripheral blood were observed after MVC therapy. However, MVC was associated with a favorable profile in HIV disease progression biomarkers only in patients with a virological response. These results support a potential clinical benefit of a therapy which includes MVC in HIV-infected patients. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
